PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
149.60%
Cash & equivalents yoy growth at least 1.5x RVPH's 95.93%. Mohnish Pabrai might see this as a favorable liquidity edge, provided funds are well deployed.
No Data
No Data available this quarter, please select a different quarter.
149.60%
Cash + STI yoy ≥ 1.5x RVPH's 95.93%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
133.42%
≥ 1.5x RVPH's 72.84%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
835.01%
Higher PP&E (Net) Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1079.37%
Higher Total Non-Current Assets Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
135.47%
≥ 1.5x RVPH's 64.40%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
69.91%
Above 1.5x RVPH's 5.25%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-41.82%
Similar yoy changes to RVPH's -49.51%. Walter Schloss finds a parallel approach to short-term funding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-49.13%
Less than half of RVPH's 8.21%. David Dodd sees fewer expansions in other current obligations.
-44.50%
Less than half of RVPH's 4.94%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-44.50%
Less than half of RVPH's 4.83%. David Dodd sees far fewer liability expansions relative to competitor.
7.98%
Less than half of RVPH's 45.49%. David Dodd sees fewer share issuances vs. competitor.
4.22%
Below half RVPH's -3.55%. Michael Burry suspects major net losses or high dividends vs. competitor.
-271.57%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
132.15%
1.25-1.5x RVPH's 89.71%. Bruce Berkowitz notes an above-average equity expansion.
135.47%
≥ 1.5x RVPH's 64.40%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-41.82%
Similar yoy changes to RVPH's -49.51%. Walter Schloss notes parallel total debt strategies.
-152.72%
1.25-1.5x RVPH's -102.37%. Martin Whitman is wary of heavier net leverage vs. competitor.